Cancer Family
Soft Tissue Neoplasm
CI-CAN-00000354Explore in graph →
Non-malignant441 active trials9 approved drugs183 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000354Explore in graph →
Clinical trials
2,078 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03400826 | Effects of Simvastatin on Uterine Leiomyoma Size | active not recruiting | Phase 2 | 60 | Johns Hopkins UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04022213 | A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum | active not recruiting | Phase 2 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07618377 | Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments | recruiting | Phase 1 | 10 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03069378 | A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | active not recruiting | Phase 2 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06660810 | Neoadjuvant Intralesional Injection of Talimogene Laherparepvec | active not recruiting | Phase 2 | 2 | John RiethOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 67 | University of California, IrvineOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07227649 | NAC-REPAIR for Post-surgical Pain | not yet recruiting | Phase 2 | 80 | University of ArizonaOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06087263 | Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. | active not recruiting | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07707882 | Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor(NEXPERT) | not yet recruiting | Phase 2 | 84 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT07377747 | Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma(ReLaPSe) | recruiting | — | 100 | Australia and New Zealand Sarcoma AssociationOTHER | 8 | Jul 15, 2026 | clinicaltrials |
| NCT05286801 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | active not recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07697248 | LRG GIST Patient Registry | recruiting | — | 5,000 | The Life Raft GroupOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 4 | Jul 10, 2026 | clinicaltrials |
| NCT07696169 | Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers | not yet recruiting | — | 1,000 | Shenzhen Third People's HospitalOTHER | 0 | Jul 10, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04946357 | Neoadjuvant Irradiation of Extremity Soft Tissue Sarcoma With Ions(EXTREM ION) | active not recruiting | N/A | 42 | University Hospital HeidelbergOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06327477 | Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 28 | Northwestern UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03972930 | Hypofractionated Radiotherapy for Soft Tissue Sarcomas | active not recruiting | Phase 2 | 48 | University of Wisconsin, MadisonOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04821895 | Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients(GIST) | active not recruiting | — | 50 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05489237 | First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | active not recruiting | Phase 1 | 276 | IDRX, Inc., a wholly owned subsidiary of GSK, LLCINDUSTRY | 11 | Jul 2, 2026 | clinicaltrials |
| NCT06981637 | Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)(MELODY) | recruiting | Phase 2 | 81 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07134192 | Fluorescence-Guided Optimization of Sarcoma Margins(FOCUS) | recruiting | N/A | 90 | University of AarhusOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | University of FloridaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673861 | Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients(CURTAIN) | recruiting | N/A | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04488822 | A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT(PLX3397) | active not recruiting | Phase 3 | 40 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Jun 26, 2026 | clinicaltrials |
| NCT04673942 | A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors(BETA-PRIME) | active not recruiting | Phase 2 | 140 | EpicentRx, Inc.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03069469 | Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | active not recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jun 25, 2026 | clinicaltrials |
| NCT05676099 | TSC Biosample Repository and Natural History Database | recruiting | — | 5,000 | National Tuberous Sclerosis AssociationOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT07664956 | Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy | not yet recruiting | Phase 4 | 36 | Christiana Care Health ServicesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03818412 | Circulating Tumor DNA in Soft Tissue Sarcoma | recruiting | N/A | 40 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05180695 | HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas(AMPHISARC) | active not recruiting | Phase 1 / Phase 2 | 47 | Centre Leon BerardOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05526417 | Individualized Prehabilitation for Enhancing Recovery and Surgical Outcomes in Patients Undergoing Radiotherapy and Surgery for Soft Tissue Sarcoma | recruiting | N/A | 33 | Mayo ClinicOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07661342 | DEPART Study at Yale(Dupuytren's) | not yet recruiting | Phase 3 | 158 | Yale UniversityOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04616248 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | active not recruiting | Phase 1 | 14 | University of Southern CaliforniaOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06571734 | XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma | recruiting | Phase 2 | 73 | Northwestern UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07502885 | Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients | recruiting | — | 300 | St. Jude Children's Research HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07656909 | Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP | recruiting | Phase 2 / Phase 3 | 76 | Yi JiOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03050268 | Familial Investigations of Childhood Cancer Predisposition(SJFAMILY) | recruiting | — | 1,500 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT04534127 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia | recruiting | N/A | 56 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT07646080 | Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans | not yet recruiting | Phase 2 | 20 | Yanjie Zhang, MDOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT07647198 | FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence(FATIMA) | recruiting | Phase 2 | 240 | Sheikh Shakhbout Medical CityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 21, 2026source: clinicaltrials